|
【参考文献】
1 Chang JHM, Wakefield D. Uveitis: a global perspective. Ocul Immunol
Inflamm 2002;10(4)：263279
2 Mercanti A, Parolini B, Bonora A, et al. Epidemiology of endogenous uveitis in noah.eastern Italy. Analysis of 655 new cases. Acta Ophthalmol
Scand 2001;79(1)：6468
3杨培增,张震,王红,等.葡萄膜炎的临床类型及病因探讨.中华眼底病杂志 2002;18(4)：253255
4 Rai G, Saxena S, Kumar H, et al. Human retinal Santigen：T cell epitope mapping in posterior uveitis patients. Exp Mol Pathol 2001;70(2)：140145
5 Li B, Yan g PZ, Zhou HY, et al. T·bet expression is upregulated in active Behcet s disease. Br J Ophthalmol 2003;87(10)：12641267
6 Ahn JK, Seo JM, Yu J, et al. Dow nregulation of IFNgamm aproducing CD56 T cels after com bined lowdose cyclosporine/prednisone treatment in patients with Behcets uveitis. Invest Ophthalmol Vis Sci 2005;46(7)：24582464
7 Ishikawa T, Hokama H, Katagiri Y, et al. Effects of intravitreal injection of tacrolimus(FK506)in experimental uveitis. Curr Eye Res 2005;30(2)：93101
8 Jonas JB, Kreissig I, Degenrmg R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87(1)：2427
9 Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmo1 2005;40(1)：6368
10 KOtter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa2a for the treatment of Behcet s disease with sisht threatening posterior or panuveitis. Br J Ophthalmol 2003;87(4)：423431
11 Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110(7)：14491453
12 Foster CS, Vital AT, eds. Diagnosis and treatment of uveitis.Philadelphia：W B Saundem 2002:177214
13 Thurau SR, Wildner G. Oral tolerance for treating uveitinew hope for an old immunological mechanism. Prog Retin Eye Res 2002;21(6):577589
14史伟云,刘延,谢立信,等.FKS06缓释系统前房植入抑制兔高危角膜移植术后的免疫排斥反应.中华眼科杂志 2006;42(4):299304
15 Abu E1Asrar AM, A1Mansouri S, Tabbeta KF, et al. Immun opathogenesis of conjunctival remodelling in vernal keratoconjunctivitis.
Eye 2006;20(1)：7179
16 Shoji J, Inada N, Sawa M. Antibody arraygenerated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J Ophthalmol 2006;50(3)：195204
17 Pappa A, Lawson JM, Calder V, et al. T cell and fibroblasts in affected extraocular muscles in early and 1ate thyroid associated ophthalmopathy. Br J Ophthalmol 2000;84(5)：517522
18 Mysliwiec J, Kretowski A, Topolska J, et al. The influence of corticostemids on IL6/IL6R system in patients with Graves’ ophthalmopathy. Pol Arch Med Wen 2002;108(2)：739744
19 Mysliwiec J, Kretowski A, Topolska J, et al. Serum Thl and Th2 profile cytokine level changes in patients with Graves’ophthalmopathy treateel with corticostemids. Horm Metab Res 2001;33(12)：739743
20陈德才,朱泓,陈红艳,等.甲基强的松龙与地塞米松加氨甲蝶呤冲击治疗Graves眼病的近期手术疗效观察.中华内分泌代谢杂志 2002;18(4)：321322
21 Smith JR, Rosenbaum JT. A role for methotrexate in the management of noninfectious orbital inflammatory disease. Br J Ophthalmol 2001;85(10)：12201224
22 Weissel M, Hauff W. Fatal liver failure after high.dose glucocorticold pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000;29(10)：521
23杨钧.现代眼科手册.北京：人民卫生出版社 1993:563
24杨培增.我国眼免疫学研究50年概况.中华眼科杂志 2000;5(36):217222 上一页 [1] [2] |
